Thiraviam Pillai Rameshwari Ammal Kannan
Overview
Explore the profile of Thiraviam Pillai Rameshwari Ammal Kannan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malvi S, Esmy P, Muwonge R, Joshi S, Poli U, Lucas E, et al.
J Natl Cancer Inst Monogr
. 2024 Nov;
2024(67):317-328.
PMID: 39529521
Background: While recommending a human papillomavirus (HPV) single-dose vaccination schedule in 2022, the World Health Organization highlighted the need for long-term follow-up studies to monitor waning of protection. We report...
2.
Bhatla N, Muwonge R, Malvi S, Joshi S, Poli U, Lucas E, et al.
Hum Vaccin Immunother
. 2023 Dec;
19(3):2289242.
PMID: 38078840
Long-term follow-up of a cohort of unmarried girls who received one, two, or three doses of quadrivalent HPV vaccine, between 10 and 18 years of age, in an Indian multi-centric...
3.
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, et al.
Vaccine
. 2022 Nov;
41(1):236-245.
PMID: 36446654
Background: The recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income...
4.
Basu P, Malvi S, Joshi S, Bhatla N, Muwonge R, Lucas E, et al.
Lancet Oncol
. 2021 Oct;
22(11):1518-1529.
PMID: 34634254
Background: A randomised trial designed to compare three and two doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent girls in India was converted to a cohort study after suspension...
5.
Muwonge R, Basu P, Gheit T, Anantharaman D, Verma Y, Bhatla N, et al.
PLoS One
. 2020 Dec;
15(12):e0244242.
PMID: 33373380
In context of the ongoing multi-centric HPV vaccine study in India, unvaccinated married women (N = 1484) aged 18-23 years were recruited in 2012-2015 as age-matched controls to the vaccinated...
6.
Basu P, Muwonge R, Bhatla N, Nene B, Joshi S, Esmy P, et al.
Papillomavirus Res
. 2019 Feb;
7:75-81.
PMID: 30711698
Earlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India...
7.
Bhatla N, Nene B, Joshi S, Esmy P, Poli U, Joshi G, et al.
Papillomavirus Res
. 2018 Mar;
5:163-171.
PMID: 29578097
Extending two-dose recommendations of HPV vaccine to girls between 15 and 18 years will reduce program cost and improve compliance. Immunogenicity and vaccine targeted HPV infection outcomes were compared between...
8.
Sankaranarayanan R, Prabhu P, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al.
Lancet Oncol
. 2015 Dec;
17(1):67-77.
PMID: 26652797
Background: An increase in worldwide HPV vaccination could be facilitated if fewer than three doses of vaccine are as effective as three doses. We originally aimed to compare the immunogenicity...